TechInvention and Quantoom Biosciences Collaborate on RNA-Based Vaccines
The partnership will advance the accessibility, scalability, and affordability of RNA-based vaccines.
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com
Belgium-based Quantoom Biosciences announced on March 5, 2025 that it is collaborating with TechInvention Lifecare Pvt. Ltd. for the accessibility, scalability, and affordability of RNA-based vaccines. The Memorandum of Understanding (MoU) was signed on March 4 during the Belgian Economic Mission to India.
TechInvention will use Quantoom’s RNA N-Force toolbox to de-risk and accelerate the development of RNA-based vaccines from sequence design with Quantoom’s Ncode, RNA production with its Ntensify product, and encapsulation with the lipid-like delivery chemistry in bulk with Ncapsulate. TechInvention will use Quantoom’s translation research and regulatory expertise and its good manufacturing practice (GMP) manufacturing capabilities to develop and commercialize novel RNA-based products. TechInvention plans to be GMP-ready at Ntensify midi scale by the end of 2025.
“This partnership represents a transformative milestone in India’s biotechnology landscape, establishing end-to-end mRNA production capabilities at TechInvention’s forthcoming EU [European Union]-GMP-approved facility, the Global Collaborative Centre for Medical Countermeasures (GCMC), in Mumbai,” Quantoom stated in a press release (1).
The collaboration will also extend to animal and environmental health, according to Quantoom, with environmentally sustainable technology that integrates modular, low-carbon-footprint messenger RNA (mRNA) systems that support decarbonization and worldwide efforts to provide access to next-generation RNA technologies.
“At Quantoom, our mission is to enable our partners to accelerate their m(sa)RNA-based vaccines development, thanks to our end-to-end N-Force Toolbox,” José Castillo, CEO, Quantoom Biosciences, said in a press release. “We think that our technology will, by design, make RNA products accessible and scalable globally. Partnering with TechInvention in India is a vital step toward achieving this goal, into the most populated country in the world, and we look forward to enabling groundbreaking developments in the field of RNA-based medicines.”
“We are excited to bring Quantoom’s cutting-edge mRNA technology to India, revolutionizing RNA drugs development and manufacturing,” Syed Ahmed, director and CEO, TechInvention, said in the release. “This partnership is a significant step toward strengthening India’s preparedness for future pandemics while ensuring broader access to RNA-based innovations across LMICs [low- and middle-income countries].”
In February 2025, Quantoom announced the signing of an MoU with EVA Pharma and DNA Script to develop the first digital-to-biologics, end-to-end mRNA production platform (2). The partnership will focus on nucleic acid-based vaccines for human and animal health. The platform will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify and Ncapsulate and will be combined with EVA Pharma’s vaccine development and GMP sterile manufacturing capabilities.
“This moment will reshape African and global health security as we know it,” Riad Armanious, CEO of EVA Pharma, said in the February press release (2). “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”
“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable,” Marc Montserrat, CEO of DNA Script, said in the release. “By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we’re helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”
“This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations,” José Castillo, CEO of Quantoom Biosciences, added.
References
- Quantoom. India and Belgium Unite to Advance RNA-Based Vaccines: MoU Signed Between Techinvention and Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to India. Press Release. March 5, 2025.
- Quantoom. Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences. Press Release. Feb. 5, 2025
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
